Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Articles by Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings
5